~~<i id='5FCDA1A336'><strike id='5FCDA1A336'><tt id='5FCDA1A336'><pre id='5FCDA1A336'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：hotspot 2025-08-12 08:27:52 - browse：76151

The FDA has taken a big step in encouraging drug companies to include pregnant women in clinical trials, issuing a draft guidance outlining how to do so safely and ethically.

Nearly 4 million women in the U.S. give birth each year, but few drugs have been approved as safe and effective to use during pregnancy. The new guidance aims to help drug companies address those information gaps “through judicious inclusion of pregnant women in clinical trials and careful attention to potential fetal risk.”

Experts say it’s a sign of progress on an issue that’s long plagued pregnant women and their physicians.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： HHS names first

knowledge

hotspot

focus

knowledge

explore

TheUniversityofMarylandteampreparesthepigheartfortransplant.CourtesyUniversityofMarylandSchoolofMedi

WSS

Medical student insurance fails on mental health care coverage

Biotech lab space demand falls sharply

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Designating disabled people as health disparity population is crucial

How AI helped researchers track recovery from depression

knowledge

fashion

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Doulas covered by Medicaid under New York's new plan

Hollywood unions extend contract negotiations for actors

New England Journal of Medicine addresses racist history, slavery

Duchenne breakthrough therapy leaves behind pioneering families

How Vertex's cystic fibrosis drug is changing patients' lives

Guidelines to prevent youth baseball injuries need more muscle

Experts study whether long Covid risk adds up with each reinfection

DIEP, the 'gold standard' of breast reconstruction, is under threat

EpiPen alternative approval delay highlights citizen petition issue

hotspot

How Vertex's cystic fibrosis drug is changing patients' lives

Why are Kaiser Permanente staff considering a strike?

Idaho abortion case may prompt more restrictions in other states

New Medicare drug pricing powers could soon be upended in court

The SUPPORT Act is critical to fighting the opioid crisis

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

focus

focus

knowledge

explore